Screening genes associated with elevated neutrophiltolymphocyte ratio in chronic heart failure

Guoxing Wan1, Lihua Ji1, Wenbin Xia1

  • 1Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China.

Insights

The neutrophil-to-lymphocyte ratio (NLR) can predict heart failure (HF) prognosis. Researchers identified three key genes—SLC22A4, IL1R2, and VNN3—independently associated with elevated NLR in chronic heart failure (CHF) patients.

Area of Science:

  • Biomarkers and Cardiovascular Disease Research
  • Genomics and Molecular Biology
  • Immunology and Inflammation

Background:

  • The neutrophil-to-lymphocyte ratio (NLR) is a recognized prognostic marker in cardiovascular diseases, but its predictive accuracy for heart failure (HF) is limited.
  • Identifying factors associated with elevated NLR could enhance prognostic predictions in HF patients.

Purpose of the Study:

  • To identify key genes associated with elevated NLR in patients with chronic heart failure (CHF).
  • To investigate the independent association of these genes with elevated NLR in CHF.

Main Methods:

  • Analysis of gene expression profiles, hematological parameters, and clinical data from 197 CHF patients (GSE77343 database).
  • Identification of differentially expressed genes (DEGs) using Pearson correlation and logistic regression.
  • Gene Ontology and pathway enrichment analyses, and protein-protein interaction network construction.
  • Utilized receiver operating characteristic (ROC) curves to assess predictive power.

Main Results:

  • Initially identified 31 DEGs associated with elevated NLR, enriched in neutrophil activation, immunity, fluid shear stress, atherosclerosis, and cancer-related transcriptional misregulation.
  • A mean NLR of 3.96 was established as the cutoff value.
  • Solute carrier family 22 member 4 (SLC22A4), interleukin-1 receptor 2 (IL1R2), and vanin 3 (VNN3) were identified as independently associated with elevated NLR in CHF.

Conclusions:

  • The genes SLC22A4, IL1R2, and VNN3 are potential decisive factors independently associated with elevated NLR in CHF patients.
  • These genes may improve the prognostic value of NLR in heart failure management.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
978
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.9K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
927
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
990
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
342